Tiligada E, Aslanis D, Delitheos A, Varonos D
Department of Experimental Pharmacology, Medical School, University of Athens, M. Asias 75, Athens, GR-11527, Greece.
Pharmacol Res. 2000 Jun;41(6):667-70. doi: 10.1006/phrs.1999.0637.
Compound 48/80 was applied into one eye of male Wistar rats and a drop of vehicle into the contralateral eye. Another group of rats received sodium cromoglycate in both eyes every 6 h for a period of 48 h. One eye was challenged with compound 48/80 30 min after the end of treatment with sodium cromoglycate. The eyes were monitored clinically and the histamine content of the conjunctiva was determined fluorometrically. The basal histamine levels in rat conjunctival homogenates were quantified. Pharmacologically-induced mast cell degranulation by a single application of 0.1 g ml(-1)of compound 48/80 resulted in significant decreases of conjunctival histamine levels 1, 12 and 24 h after challenge. Sodium cromoglycate prevented the effect of compound 48/80 when administered into the eye prior to the challenge with the non-immunogenic histamine releaser. Upon termination of the application, the membrane stabilizer was unable to reverse the reduced histamine levels in the conjunctival homogenates.
将化合物48/80滴入雄性Wistar大鼠的一只眼睛,对侧眼睛滴入一滴赋形剂。另一组大鼠每6小时在双眼滴入色甘酸钠,持续48小时。在用色甘酸钠治疗结束后30分钟,用化合物48/80刺激一只眼睛。对眼睛进行临床监测,并通过荧光法测定结膜的组胺含量。对大鼠结膜匀浆中的基础组胺水平进行定量。单次应用0.1 g/ml的化合物48/80进行药理学诱导的肥大细胞脱颗粒,导致刺激后1、12和24小时结膜组胺水平显著降低。在用非免疫原性组胺释放剂刺激前,将色甘酸钠滴入眼内可预防化合物48/80的作用。在应用终止后,膜稳定剂无法逆转结膜匀浆中降低的组胺水平。